Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 5/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005863 | 0.72 | CYP3A4 (0.40) | CYP3A4ALDH1A1 | |
| SCHEMBL7662173 | 0.72 | — | — | |
| SCHEMBL6558866 | 0.70 | CYP3A4 (0.35) | CYP3A4ALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL147649 | 0.67 | NOTUM (0.32) | — | |
| SCHEMBL8122181 | 0.67 | NOTUM (0.33) | — | |
| SCHEMBL9781175 | 0.64 | GPR35 (0.47) | CYP3A4ALDH1A1HPGDTSHRMAPK1 | |
| SCHEMBL9785733 | 0.63 | AHR (0.50) | ALDH1A1TSHRAHR | |
| SCHEMBL10599581 | 0.63 | CYP2A6 (0.40) | ALDH1A1HPGDHSD17B10TSHRHSP90AA1 | |
| SCHEMBL1392086 | 0.63 | — | — | |
| SCHEMBL1392648 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106232120-B | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2- (1H) -ones | 爱尔皮奥治疗有限公司 | 2021-01-08 | — | — | CN | claimed |
| EP-3107542-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | Aerpio Therapeutics, Inc. (US) | 2016-12-28 | — | — | EP | claimed |
| CN-106232120-A | The method preparing N benzyl 3 hydroxyl 4 substituted pyridine 2 (1H) ketone | 爱尔皮奥治疗有限公司 | 2016-12-14 | — | — | CN | claimed |
| US-9388135-B2 | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones | AERPIO THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | claimed |
| WO-2015126860-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS, INC. | 2015-08-20 | — | — | US | claimed |
| US-8975259-B2 | Compositions and methods for inhibiting G protein signaling | UNIVERSITY OF ROCHESTER (US) | 2015-03-10 | — | — | US | claimed |
| EP-2190466-A2 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | Burnham Institute for Medical Research (US) | 2010-06-02 | — | — | EP | claimed |
| US-20100130505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | UNIVERSITY OF ROCHESTER (US) | 2010-05-27 | — | — | US | claimed |
| EP-2147310-A2 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | University of Rochester (US) | 2010-01-27 | — | — | EP | claimed |
| WO-2009020677-A9 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | UNIV ROCHESTER (US) | 2009-04-16 | — | — | WO | claimed |
| WO-2009042294-A2 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-02 | — | — | WO | claimed |
| US-20090053192-A1 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-26 | — | — | US | claimed |
| WO-2009020677-A2 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | UNIVERSITY OF ROCHESTER (US) | 2009-02-12 | — | — | WO | claimed |
| EP-0463488-B2 | O-Benzyl oxime ethers and fungicides containing them | BASF AG (DE) | 2004-04-21 | — | — | EP | claimed |
| US-4714734-A | POLYSILOXANE CONTAINING AROMATIC RING CONSTITUENT HAVING SMALL'S MOLECULAR ATTRACTION CONSTANT NOT SMALLER THAN 350 | BRIDGESTONE CORP. (JP) | 1987-12-22 | — | — | US | claimed |
| US-4629495-A | Herbicidal 5-amino-4-cyano-1-phenylpyrazoles | MAY & BAKER LIMITED (GB) | 1986-12-16 | — | — | US | claimed |
| WO-2022270375-A1 | COMPOSITION | 住友化学株式会社 | 2022-12-29 | — | — | WO | disclosed |
| EP-0024485-A1 | Process for the production of ethylene copolymers with at least one other 1-monoolefin and optionally a non conjugated diene | CHEMISCHE WERKE HÜLS AG (DE) | 1981-03-11 | — | — | EP | disclosed |
| US-4181790-A | A 2,3,4,4-TETRACHLORO-3-BUTENOATE | Chemische Werke Huels, Aktiengellschaft (DE) | 1980-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | CYP4B1, CYP8B1, HPD | CYP3A4 4/4885ALDH1A1 1501/4885HPGD 164/4885 |
| US-20100130505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING | GNAI1, GNAI3, GNAI2 | CYP3A4 4860/4885ALDH1A1 4720/4885HPGD 2169/4885 |
| US-20090053192-A1 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | ALPL, ALPP, ACP3 | CYP3A4 4763/4885ALDH1A1 3056/4885HPGD 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.